SC 13G

Company

Viking Therapeutics, Inc.

Filed

February 12, 2018

Accession Number

0001193125-18-040234

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →